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ABSTRACT
Objective: A present investigation is based on method development and validation for the simultaneous determination of metoprolol and atorvastatin 
by reversed-phase high-performance liquid chromatography in its bulk and pharmaceutical dosage form using a biorelevant dissolution media (fasted 
state small intestinal fluid).
Methods: The chromatographic separation technique performed by an isocratic method for this column used Inertsil ODS-3 (4.6×150 mm, 5 µm). The 
ratio of mobile phase used is phosphate buffer 4.8 pH: acetonitrile (35:65v/v), flow rate 1 ml/min, and analysis time 15.0 min, UV detection was at 244 nm.
Results: According to the International Conference on Harmonisation Q2 (R1) guidelines, the method validation was done. Peaks were observed at 
2.227 min and 5.819 min, concentration range of linearity was obtained at 50–250 μg/ml and 10–50 μg/ml, linearity correlation coefficients were 
0.9997 and 0.9995, limit of detection was 0.33 mg/ml and 0.21 mg/ml, and limit of quantification was 1.08 mg/ml and 0.69 mg/ml for metoprolol 
and atorvastatin, respectively.
Conclusion: The obtained results for this method validation are within acceptance criteria. This method was more economical and stable for routine 
analysis.
Keywords: Metoprolol and atorvastatin, Reversed-phase high-performance liquid chromatography, Method development, Validation, International 
Conference on Harmonisation Q2 (R1), Biorelevant dissolution media (fasted state small intestinal fluid).
INTRODUCTION
Metoprolol  acts  as  a  competitive  β1-adrenergic  receptor  antagonist 
agent [1,2] (cardioselective) used as the antihypertensive agent. 
Antagonist activity of this agent is mainly because of more substituents 
present on the para position [3,4]. It shows membrane-stabilizing effects 
prescribed at a high dose than the dose required to show antagonist 
property [5]. The IUPAC name for metoprolol is 1-[4-(2-methoxyethyl]
phenoxy]-3-(propan-2-ylamino)propan-2-ol. Chemical structure for 
metoprolol is shown in Fig. 1.
Atorvastatin is a statin and used as the lipid-lowering agent. It decreases 
the cholesterol levels by inhibiting the 3-hydroxy-3-methylglutaryl 
(HMG)-CoA enzyme because, in mevalonate pathway, it is a rate-
determining enzyme in cholesterol. Atorvastatin primarily [6,7] acts 
on the liver and selectively inhibits the release of HMG-CoA reductase 
enzyme. HMG-CoA reductase is responsible for converting HMG-CoA 
to mevalonate in the cholesterol biosynthesis, and by this enzyme, 
conversion reaction prevents the synthesis of hepatic cholesterol [7-9]. 
It will encourage the hepatic uptake of cholesterol and decreases serum 
cholesterol levels by stimulation of hepatic low-density lipoprotein-
cholesterol receptors [10]. The IUPAC name for atorvastatin is (3R, 
5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-
2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid. Chemical structure for 
Atorvastatin is shown in Fig. 2.
From literature review [11-26], we found that there were no methods 
available for simultaneous determination of metoprolol and atorvastatin 
in a combined dosage form by reversed-phase high-performance liquid 
chromatography (RP-HPLC) using biorelevant dissolution media. 
This research work denotes a novel, economical, accurate, precise, 
specific, robust, rugged RP-HPLC method developed in the selected 
solvent system (mobile phase) in biorelevant dissolution media (fasted 
state small intestinal fluid [FaSSIF]) [27-31], and the validation was 
performed as per the International Conference on Harmonisation (ICH) 
Q2 (R1) guidelines [32].
MATERIALS AND METHODS
Reagents and chemicals
The metoprolol and atorvastatin pure standards were supplied by 
Syncorp Clincare Pvt. Ltd., Dilsuknagar, Hyderabad. The marketed 
formulation tablets labeled to contain 50 mg of metoprolol and 10 mg of 
atorvastatin, manufactured by Emcure Pharmaceuticals Ltd. (Metpure 
St), were obtained from the market. Analytical reagent grade and HPLC 
Grade chemicals procured from SD Fine-Chem Ltd., Mumbai (Mumbai, 
India) were used in the research.
Instruments used
The instrument was used Waters HPLC (717 series), Inertsil ODS-3 
column, UV detector, data handling system EMPOWER2 software, UV-
Visible double beam spectrophotometer (Labindia), analytical balance 
0.1mg sensitivity (SHIMADZU), pH meter (Labindia), and ultrasonicator.
Blank FaSSIF
Weigh and dissolve NaOH (1.74 g), NaH2PO4 (19.77 g), and NaCl 
(30.93 g) in 5 L of HPLC grade distilled, and the pH was adjusted to 6.5 
by using 1N HCl.
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Diluent
Weigh and dissolve 3.3 g sodium taurocholate in approximately 500 ml 
of blank FaSSIF. Then, add 11.8 ml of methylene chloride solution 
containing 100 mg/ml of lecithin, and it produces an emulsion which is 
turbid. This solution was subjected to vacuum at a temperature of about 
40°C under pressure at 500 mbar for 10 min and followed by 30 min 
at 10 mbar to get a clear solution. After that the solution was cooled to 
27°C and make up the volume to 2 L with blank FaSSIF.
Stock solutions
Weigh and transfer pure 10 mg of metoprolol and atorvastatin 
separately into 10 ml volumetric flasks. Then, add 7 ml of diluent 
and ultrasonicated for 15 min. Filter the solution using membrane 
filter paper (0.45 µm), and volume make up to 10 ml using the same 
diluent. Five levels of linearity concentrations were prepared by mixed 
appropriately and  further diluted  to get 50–250 μg/ml of metoprolol 
and  10–50  μg/ml  of  atorvastatin.  Inject  the  series  concentrations  in 
triplicate into the column, and the average peak areas are recorded 
from chromatograms. Linearity graph was plotted peak area against 
concentrations.
Mixed working solution
To prepare separately 1 mg/ml of metoprolol and atorvastatin solution 
by using stock solution. From this above solutions, pipette out 1 ml 
of metoprolol solution and 0.1 ml of atorvastatin solution into a 




According to I.P method, take twenty tablets and weighed. Then, the 
tablets are triturated in a mortar to get smooth powder. The amount of 
drug present in a powder which is equivalence to standard drug of 10 mg 
of atorvastatin. The powder was transferred to a 100 ml of volumetric 
flask and add approximately 70 ml of diluent, and the resulted solution 
was subjected to sonication for 15 min by using ultrasonicator, Then, 
the solution was filtered using membrane filter paper (0.45 µm) and 
volume make up to 100 ml using the same diluent. From this, take 1 ml 
and transfer to six 10 ml volumetric flasks, and then, the volume was 
made up mark with the diluent. These solutions are injected 3 times 
each sample solution into the column and the results are mentioned as 
a function of mean of all replicas.
Study of spectra and selection of wavelength
Working standard solutions were scanned an entire range of UV in a 
1 cm cell against blank using UV-spectrophotometer. The absorption 
maxima of metoprolol and atorvastatin were selected from spectral 
data, and isosbestic wavelength was selected from overlain spectra of 
UV spectrophotometer. An isosbestic point was found to be at 244 nm. 
The UV spectrum of metoprolol and atorvastatin is shown in Fig. 3.
Optimization of HPLC method
The column used in this method was performed on Inertsil ODS-
3(4.6×150 mm, 5 µm). The method was optimized with a mobile phase 
as its composition phosphate buffer 4.8 pH and acetonitrile (35:65v/v) 
that run isocratically; conditions were optimized with the rate at which 
mobile phase runs at 1.0 ml/min, UV detection at 244 nm, and analysis 
time was 15.0 min.
Validation of method
This method was validated according to the ICH Q2 (R1) guidelines. 
The validation parameters performed were system suitability, linearity 
range, accuracy data, precision (intra and inter), limit of detection 
(LOD), limits of quantification (LOQ), and robustness.
Forced degradation studies
Active pharmaceutical ingredients of metoprolol and atorvastatin 
were subjected to keep in degradation ways and find the extent of 
degradation of a product by this method. The parameters were carried 
out for forced degradation studies are acid, base, peroxide, thermal and 
photo degradation.
RESULTS AND DISCUSSION
Method development and optimized method
This method was accurate, specific, linear, precise, and suitable for 
the analysis of metoprolol and atorvastatin by RP-HPLC method. The 
HPLC instrument comprised a Waters HPLC with autosampler and 
UV detector. The Inertsil ODS-3 (4.6×150 mm, 5 µm) column is used. 
The ratio of mobile phase used is phosphate buffer 4.8 pH: acetonitrile 
(35:65v/v). Mode of separation is isocratic and its temperature of the 
column is ambient. The optimized chromatographic conditions are 
mentioned in Table 1 and chromatograms are shown in Figs. 4-7.
Assay
The assay study was performed for the metoprolol and atorvastatin in 
marketed tablet dosage form. For each determination, 3 times inject the 
solution into the column. The assay chromatogram is shown in Fig. 8 
and the results are mentioned in Table 2.
Fig. 1: Chemical structure of metoprolol
Fig. 2: Chemical structure of atorvastatin
Fig. 3: Overlay spectrum for isosbestic point
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Method validation
This method was validated according to the ICH Q2 (R1) guidelines for 
various parameters.
Suitability
The mixed working solution was injected six replicates into the 
chromatographic column. The mean of suitability parameters was calculated 
from the obtained chromatogram. Results are tabulated in Tables 3 and 4.
Linearity and range
The linearity study was performed for the series concentrations 
50–250  μg/ml  and  10–50  μg/ml  of  metoprolol  and  atorvastatin, 
Table 1: Optimized conditions
Optimization parameters Method conditions
Stationary phase Inertsil ODS-3 (4.6×150 mm, 5 µm)
Mobile phase Phosphate buffer 4.8 pH and 
acetonitrile (35:65 v/v)
pH 4.8±0.02
Flow rate 1.0 ml/min
Analysis time each injection 15.0 min
Temperature of column Ambient °C
Fixed injection loop volume 20 µl
Detection wavelength 244 nm
Drugs retention time 2.227 and 5.819 min
Table 2: Assay data for marketed tablets
Tablet (Metpure St) Label claim (mg) Amount estimated* (mg) Amount estimated (%) Acceptance range (%)
Metoprolol 50 50.05 100.10 98–102
Atorvastatin 10 10.06 100.66
*Mean of three determinations
Fig. 4: Chromatogram for blank preparation
Fig. 5: Chromatogram for standard metoprolol
Fig. 6: Chromatogram for standard atorvastatin
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Fig. 7: Chromatogram for mixed standard metoprolol and atorvastatin at 244 nm from bulk drug
Fig. 8: Chromatogram for metoprolol and atorvastatin at 244 nm from pharmaceutical dosage form (Metpure St)
Table 3: System suitability for metoprolol and atorvastatin
Parameter Metoprolol Atorvastatin
Retention time (min) 2.227 5.819
Resolution (Rs. >2) 3.11 3.19
Asymmetry (T£2) 0.14 0.29
Theoretical plates 3941 2843
Tailing factor 1.54 1.84
Table 4: System suitability (peak area and Rt) for metoprolol and atorvastatin
Injection Peak area for metoprolol Peak area for atorvastatin Rt for metoprolol Rt for atorvastatin
Injection-1 1,235,278 436,704 2.216 5.811
Injection-2 1,220,850 435,672 2.223 5.816
Injection-3 1,239,231 439,902 2.217 5.831
Injection-4 1,212,072 435,887 2.228 5.840
Injection-5 1,237,137 442,806 2.214 5.813
Injection-6 1,228,702 444,747 2.223 5.832
Average 1,228,878.3 439286.3 2.220 5.800
Standard deviation 10613.9 3843.8 0.00534478 0.00
% RSD 0.9 0.9 0.2 0.206454877
Rt: Retention time, RSD: Relative standard deviation
respectively. The obtained values are tabulated in Tables 5 and 6. 
The graph for both the drugs is shown in Figs. 9-10 and overlay 
chromatogram in Fig. 11.
Accuracy
The accuracy study was performed for 80, 100, and 120% for 
metoprolol and atorvastatin. Each level was injected in triplicate into a 
chromatographic column. The area of each level was used for calculation 
of % recovery drug. The results are tabulated in Tables 7 and 8.
Precision
The study of precision in this method was based on intraday and 
interday variations. The working standard solutions of metoprolol and 
atorvastatin have injected six replicas on the same day and on three 
different days for three different levels of concentrations. The mean 
and percentage relative standard deviation (% RSD) are tabulated in 
Tables 9 and 10. The results obtained all are within acceptable limits 
(% RSD <2).
LOD and LOQ
For metoprolol and atorvastatin, LOD was found to be 0.33 mg/ml and 
0.21 mg/ml and LOQ was found to be 1.08 mg/ml and 0.69 mg/ml, 
respectively. The obtained values are tabulated in Table 11.
Robustness
It is a prediction of reliability for method development to maintain 
stable and unaffected the results are obtained by small changes 
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Table 7: Accuracy data for metoprolol
Sample Id Concentration (µg/ml) % Recovery Statistical data
Pure drug Amount added
S1: 80% 80 100 100.19 Mean=100.17%
SD=0.200083
% RSD=0.202152
S2: 80% 80 100 100.17
S3: 80% 80 100 100.16
S4: 100% 100 100 100.39 Mean=100.40%
SD=0.33
% RSD=0.331525
S5: 100% 100 100 100.4
S6: 100% 100 100 100.43
S7: 120% 120 100 100.67 Mean=100.68%
SD=0.33
% RSD=0.331159
S8: 120% 120 100 100.71
S9: 120% 120 100 100.68
RSD: Relative standard deviation
Table 8: The accuracy data for atorvastatin
Sample Id Concentration (µg/ml) % Recovery Statistical data
Pure drug Amount added
S1: 80% 80 100 100.61 Mean=100.62%
S2: 80% 80 100 100.64 SD=0.198578
S3: 80% 80 100 100.62 % RSD=0.199884
S4: 100% 100 100 100.84 Mean=100.84%
S5: 100% 100 100 100.81 SD=0.032146
S6: 100% 100 100 100.89 % RSD=0.03242
S7: 120% 120 100 100.41 Mean=100.40%
S8: 120% 120 100 100.46 SD=0.040415
S9: 120% 120 100 100.45 % RSD=0.04068




Mean % RSD Mean % RSD
80 80.05 1.02 79.59 0.98
100 99.94 0.74 100.09 0.56
120 119.97 0.35 120.006 0.32
RSD: Relative standard deviation




Mean % RSD Mean % RSD
80 80.04 0.24 79.76 0.22
100 100.45 0.35 100.12 0.33
120 119.16 0.15 120.20 0.18
RSD: Relative standard deviation
Table 5: Linearity results: (For metoprolol)







Table 6: Linearity results: (For atorvastatin)







were made in method development. The robustness data conducted 
for variations in flow rate and percentage of composition in the 
mobile phase were performed. The obtained values are tabulated in 
Tables 12- 13.
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Fig. 9: Calibration curve of metoprolol
Fig. 10: Calibration curve of atorvastatin
Table 13: Robustness data for variation in percentage of 
composition in the mobile phase
Drug Percentage of 







Metoprolol 10% less 1.55 3445.74
*Actual 1.56 3399.02
10% more 1.52 3427.53
Atorvastatin 10% less 1.43 5082.74
*Actual 1.36 5167.98
10% more 1.43 5667.09
*Results from assay standard
Table 14: Degradation results for metoprolol and atorvastatin
Sample name Metoprolol Atorvastatin
Area % Degraded Area % Degraded
Standard 1214803 426473
Acid 1196736 1.49 416562 2.32
Base 1175633 3.22 410776 3.68
Peroxide 1097863 9.63 407623 4.42
Thermal 1167563 3.89 403572 5.37
Photo 1165552 4.05 398772 6.50
Fig. 12: Acidic degradation
 Fig. 11: Overlay report for linearity




LOD: Limit of detection, LOQ: Limits of quantification
Table 12: Robustness data for variation in flow rate





Metoprolol 0.9 1.53 3391.33
*1 1.56 3399.02
1.1 1.57 3418.14
Atorvastatin 0.9 1.82 2803.28
*1 1.84 2843.08
1.1 1.86 2892.46
*Results from assay standard
Forced degradation studies
The data obtained in forced degradation studies reveal that the 
developed method is more stable in some stress conditions. Metoprolol 
was stable in thermal and photolytic (degradation) stress conditions, 
and the atorvastatin was comparatively stable in oxidation degradation. 
The obtained values are tabulated in Table 14, and chromatograms are 
shown in Figs. 12-16.
CONCLUSION
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Fig. 13: Alkaline degradation
Fig. 14: Thermal degradation
Fig. 15: Oxidative degradation
Fig. 16: Photolytic degradation
The obtained results for this method validation are within acceptance 
criteria. This method was more economical and stable. This 
method could selectively quantify metoprolol and atorvastatin in a 
pharmaceutical tablet dosage form. From the obtained experimental 
data, the developed method is more accurate, precise, and selective, 
so this method was suitable for routine analysis successfully for this 
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combination in its bulk and marketed formulations by RP-HPLC using 
biorelevant dissolution media (FaSSIF).
REFERENCES
1. Schäfer M, Frischkopf K, Taimor G, Piper HM, Schlüter KD. 
Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on 
ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol 
2000;279:C495-503.
2. Ladage D, Schwinger RH, Brixius K. Cardio-selective beta-blocker: 
Pharmacological evidence and their influence on exercise capacity. 
Cardiovasc Ther 2013;31:76-83.
3. Staudt A, Mobini R, Fu M, Grosse Y, Stangl V, Stangl K, et al. Beta(1)-
adrenoceptor antibodies induce positive inotropic response in isolated 
cardiomyocytes. Eur J Pharmacol 2001;423:115-9.
4. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, 
Langaee TY, et al. Beta-adrenergic receptor gene polymorphisms and 
beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 
2008;84:715-21.
5. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, et al. Gly389Arg 
polymorphism of beta1-adrenergic receptor is associated with 
the cardiovascular response to metoprolol. Clin Pharmacol Ther 
2003;74:372-9.
6. Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. 
Efficacy of alternate-day dosing versus daily dosing of atorvastatin. 
J Cardiovasc Pharmacol Ther 2003;8:123-6.
7. Baxter JD, Webb P, Grover G, Scanlan TS. Selective activation of 
thyroid hormone signaling pathways by GC-1: A new approach to 
controlling cholesterol and body weight. Trends Endocrinol Metab 
2004;15:154-7.
8. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, et al. 
Effect of pitavastatin on apolipoprotein A-I production in hepG2 cell. 
Biochem Biophys Res Commun 2004;324:835-9.
9. Bösel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, 
et al. Neuroprotective effects of atorvastatin against glutamate-
induced excitotoxicity in primary cortical neurones. J Neurochem 
2005;92:1386-98.
10. Chen X, Ji ZL, Chen YZ. TTD: Therapeutic target database. Nucleic 
Acids Res 2002;30:412-5.
11. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid 
Chromatography. 3rd ed. Hoboken, New Jersey: Wiley Publishers; 
2010.
12. Sangshetti JN, Aqeel M, Zaheer Z, Ahmed RZ, Dehghan MH, Gonjari I. 
Development and validation of RP-HPLC method for determination of 
atorvastatin calcium and nicotinic acid in combined tablet dosage form. 
J Saudi Chem Soc 2016;20:S328-33.
13. Peraman R, Mallikarjuna S, Ammineni P, Kondreddy VK. RP-HPLC 
method development and validation for simultaneous estimation of 
atorvastatin calcium and pioglitazone hydrochloride in pharmaceutical 
dosage form. J Chromatogr Sci 2014;52:1038-42.
14. Kurakula M, Sobahi TR, El-Helw AM, Abdelaal MY. Development 
and validation of an RP-HPLC method for assay of atorvastatin and 
its application in dissolution studies on thermosensitive hydrogel-based 
nanocrystals. Trop J Pharm Res 2014;13:1681-7.
15. Sharma R, Khanna S, Mishra GP. Development and validation 
of RP-HPLC method for simultaneous estimation of ramipril, 
aspirin and atorvastatin in pharmaceutical preparations. E-J 
Chem 2012;9:2177-84.
16. Jain N, Raghuwanshi R, Jain D. Development and validation of RP-
HPLC method for simultaneous estimation of atorvastatin calcium and 
fenofibrate in tablet dosage forms. Indian J Pharm Sci 2008;70:263-5.
17. Raul SK, Aravelli AB, Jhansi D. RP-HPLC method development and 
validation for the simultaneous estimation of atorvastatin and ezetimibe 
in pharmaceutical dosage form. Asian J Pharm Clin Res 2015;8:178-81.
18. Mawazi SM, Reddy GN. Method development and validation for 
simultaneous estimation of atorvastatin and ezetimibe in pharmaceutical 
dosage form by HPLC. World J Pharm Sci 2014;2:866-70.
19. Kumar SA, Debnath M, Rao JV, Sankar DG. New validated stability-
indicating rp-HPLC method for simultaneous estimation of atorvastatin 
and ezetimibe in human plasma by using PDA detector. Adv Pharm 
Bull 2015;5:385-91.
20. Pryanka J, Mukesh K. Development and validation of a reverse phase 
HPLC method for the simultaneous estimation of metoprolol and 
telmisartan in tablet dosage form. Pharm Sin 2011;2:211-9.
21. Venkateswararao L, Vardhan SV, Venkatrao SV, Chintala R. Validated 
RP-HPLC method for the estimation of metoprolol succinate in dosage 
formulations. Am J Pharmtech Res 2013;3:328-34.
22. Nilesh J, Kumar SB, Ruchi J, Kumar JD, Surendra J. RP-HPLC method 
development and validation for quantitative estimation of metoprolol 
succinate and telmisartan in bulk drug and their dosage forms. J Pharm 
Biomed Sci 2012;24:102-6.
23. Brijesh S, Patel DK, Ghosh SK. Development of reverse-phase 
HPLC method for simultaneous analysis of metoprolol succinate 
and hydrochlorothiazide in a tablet formulation. Trop J Pharm Res 
2009;8:539-43.
24. Tsvetkova BG, Pencheva IP, Peikov PT. Development and validation 
of RP-HPLC method for simultaneous determination of metoprolol and 
aspirin in fixed dose combinations. Pharm Chem 2012;4:1512-6.
25. Pokala M, Rani PJ, Pranathi G, Haque MA, Sireesha D, et al. 
Development and validation of rp-hplc method for the simultaneous 
estimation of amlodipine and metoprolol in bulk and pharmaceutical 
dosage form. Indo Am J Pharm Res 2015;5:3254-60.
26. Madhukar A, Kannappan N. RP-HPLC method for the simultaneous 
estimation of cilnidipine and metoprolol succinate in bulk and tablet 
dosage form in biorelevant media (FaSSIF). Int J Pharm Tech Res 
2015;7:172-84.
27. Marques M. Dissolution media simulating fasted and fed states. 
Dissolut Technol 2004;11:16.
28. Nitin BB, Adhikrao VY, Sachin SM, Rohan AK, Ashok AH, Sachin SS, 
et al. A review on development of biorelevant dissolution medium. 
J Drug Deliv Ther 2014;4:140-8.
29. Sharma MK. Bio-relevant dissolution media development. J Bioequiv 
Availab 2016;9:1-2.
30. Kostewicz ES, Brauns U, Becker R, Dressman JB. Forecasting the oral 
absorption behavior of poorly soluble weak bases using solubility and 
dissolution studies in biorelevant media. Pharm Res 2002;19:345-9.
31. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, 
poorly water-soluble drugs. Eur J Pharm Sci 2000;11 Suppl 2:S73-80.
32. ICH. Validation of Analytical Procedures: Text and Methodology Q2 
(R1). International Conference on Harmonization; 2005.
